Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montréal, QC; Segal Cancer Center, Lady Davis Institute of Medical Research, McGill University, Montréal, QC.
Department of Obstetrics and Gynecology, Yitzhak Shamir Medical Center, Tel-Aviv University, Tel-Aviv, Israel.
J Obstet Gynaecol Can. 2021 Oct;43(10):1136-1144.e1. doi: 10.1016/j.jogc.2021.04.014. Epub 2021 May 11.
Although its use in endometrial cancer staging is relatively new, sentinel lymph node (SLN) sampling has been shown to be highly accurate and is associated with few complications. However, some studies report lower rates of detection with SLN sampling among patients with obesity. The aim of the current study is to evaluate the feasibility of SLN sampling in endometrial cancer for patients with obesity, and to determine whether omitting lymph node dissection (LND) in surgical staging using SLN sampling impacts oncologic outcomes.
we conducted a retrospective study of patients with obesity (BMI ≥35 kg/m, diagnosed with endometrial carcinoma between 2007 and 2017, that compared surgical and oncologic outcomes of 2 cohorts: patients who underwent LND and patients who underwent SLN without lymphadenectomy. The primary outcome was operative time. Secondary outcomes included intraoperative bleeding; lymph node assessment information; intraoperative and postoperative adverse events; and oncologic outcomes including progression-free survival (PFS), overall survival (OS), and disease-specific survival (DSS). PFS was defined as the time from surgery to the recurrence or death from any cause. OS was defined as time from diagnosis to death or the last date the patient was known to be alive, and DSS was defined as the time from the surgery to death from the disease.
Out of 223 patients with a median BMI of 40.6 kg/m, 140 underwent LND and 83 underwent SLN alone. The median operative time for patients in the SLN group was shorter than that of patients in the LND group (190.5 [range 108-393] vs. 238 [131-440] min; P < 0.001), and the SLN group had lower median estimated blood loss than the LND group (30 [range 0-300] vs. 40 [range 0-800] mL; P = 0.03). At the 24-month follow-up cut-off, 98% of patients were alive and 95.5% were disease free, with no significant differences in OS, DSS, and PFS between the 2 groups (P = 0.7, P = 0.8, and P = 0.4, respectively).
In patients with obesity, omitting LND from surgical staging with SLN sampling was associated with shorter operative times and less bleeding and did not affect survival at 2 years.
虽然前哨淋巴结(SLN)取样在子宫内膜癌分期中的应用相对较新,但已证明其具有高度准确性,且并发症较少。然而,一些研究报告称,肥胖患者的 SLN 取样检测率较低。本研究旨在评估 SLN 取样在肥胖患者子宫内膜癌中的可行性,并确定使用 SLN 取样进行外科分期时省略淋巴结清扫术(LND)是否会影响肿瘤学结果。
我们对 2007 年至 2017 年间诊断为子宫内膜癌且 BMI≥35kg/m2 的肥胖患者进行了回顾性研究,比较了两组患者的手术和肿瘤学结果:接受 LND 的患者和接受 SLN 而未行淋巴结切除术的患者。主要结局为手术时间。次要结局包括术中出血、淋巴结评估信息、术中术后不良事件以及肿瘤学结局,包括无进展生存期(PFS)、总生存期(OS)和疾病特异性生存期(DSS)。PFS 定义为从手术到任何原因复发或死亡的时间。OS 定义为从诊断到死亡或最后一次已知患者存活的时间,DSS 定义为从手术到死于疾病的时间。
在 223 名 BMI 中位数为 40.6kg/m2 的患者中,140 名患者接受了 LND,83 名患者接受了单独的 SLN。SLN 组的中位手术时间短于 LND 组(190.5[范围 108-393] vs. 238[131-440]min;P<0.001),SLN 组的中位估计出血量低于 LND 组(30[范围 0-300] vs. 40[范围 0-800]mL;P=0.03)。在 24 个月的随访截止时间,98%的患者存活,95.5%的患者无疾病,两组之间的 OS、DSS 和 PFS 无显著差异(P=0.7、P=0.8 和 P=0.4)。
在肥胖患者中,使用 SLN 取样进行外科分期时省略 LND 与手术时间更短、出血更少相关,且不会影响 2 年的生存率。